Comparative Pharmacology
Head-to-head clinical analysis: CIPROFLOXACIN versus FLOXIN IN DEXTROSE 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CIPROFLOXACIN versus FLOXIN IN DEXTROSE 5.
CIPROFLOXACIN vs FLOXIN IN DEXTROSE 5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits DNA gyrase (topoisomerase II) and topoisomerase IV, preventing bacterial DNA replication, transcription, and repair.
Inhibits bacterial DNA gyrase (topoisomerase II) and topoisomerase IV, preventing DNA replication and transcription.
400 mg IV every 12 hours or 500 mg orally every 12 hours for uncomplicated infections; 400 mg IV every 8 hours or 750 mg orally every 12 hours for severe/complicated infections.
400 mg intravenously every 12 hours.
None Documented
None Documented
4 hours (3-5 hours) in normal renal function; prolonged to 8-12 hours in moderate renal impairment (CrCl 20-50 mL/min) and 12-24 hours in severe impairment (CrCl <20 mL/min)
Clinical Note
moderateCiprofloxacin + Digoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateCiprofloxacin + Digitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateCiprofloxacin + Deslanoside
"Ciprofloxacin may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateCiprofloxacin + Acetyldigitoxin
"Ciprofloxacin may decrease the cardiotoxic activities of Acetyldigitoxin."
Terminal elimination half-life: 6-8 hours (prolonged in renal impairment, up to 20-30 hours in severe impairment).
Renal (50-70% unchanged via glomerular filtration and tubular secretion); fecal (15-25% via biliary and transintestinal elimination); <1% as metabolites
Primarily renal (approximately 70-90% unchanged drug), with 5-10% biliary/fecal elimination.
Category C
Category C
Fluoroquinolone Antibiotic
Fluoroquinolone Antibiotic